Comparative Pharmacology
Head-to-head clinical analysis: ELOCON versus FLUOCET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELOCON versus FLUOCET.
ELOCON vs FLUOCET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Elocon (mometasone furoate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to the glucocorticoid receptor, leading to increased synthesis of lipocortins that inhibit phospholipase A2, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene formation. It also suppresses cytokine production and inflammatory cell migration.
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin into presynaptic neurons.
Apply a thin film to affected skin area once daily. Use no more than 45 g per week.
20 mg orally once daily in the morning.
None Documented
None Documented
Terminal elimination half-life approximately 5-7 hours after topical application. Systemic half-life is short, limiting systemic accumulation with topical use.
Fluoxetine: 4-6 days (single dose), 4-6 days (chronic); Norfluoxetine: 16 days. Clinical context: Steady state achieved after 4-5 weeks; extended half-life reduces withdrawal risk but prolongs washout.
Primarily hepatic metabolism; metabolites excreted renally and in feces. Approximately 60% of a topical dose is excreted in urine as metabolites, 30% in feces.
Renal: 80% as fluoxetine and its metabolites (60% as glucuronide conjugates, 20% as parent and norfluoxetine). Fecal: 15% (biliary).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid